A purple and pink letter v on a white background.
March 19, 2020

Advanced Solution for Cellulite Reduction

Cellulite is one of the top concerns among medical aesthetic patients today, with 90% of women and over 10% of men concerned about stubborn, unsightly cellulite. It is believed that most women at some point in their lifetime will experience cellulite. Many aesthetic patients are eager to diminish its orange-peel like texture with treatment alternatives that do not involve surgery or drastic lifestyle changes.

Cellulite takes the form of lumps and dimples in the skin. Although the exact cause behind it is unknown, it is the result of interactions with the connective tissue and the layer of fat below it. Cellulite is more prevalent in female patients because fat cells and connective tissue in the dermatological layer are arranged vertically rather than the male counterpart’s “crisscross” structure. When fat cells protrude the skin, it creates the appearance of cellulite.

Genetic factors, hormones, and low blood circulation can all make fat deposits more visible, leading to a higher likelihood of someone developing cellulite. A scale was developed in 2009 categorizing three grades to reference the severity of the condition.

Treatment options for patients includes small laser probes, subcisions, and carboxytherapy, which requires some sort of incision into the skin. Non-invasive alternatives using radio frequency on the other hand are comfortable for patients and work to deliver energy under the skin to heat tissues. Venus Legacy™ is a device that incorporates such technology with Pulsed Electro Magnetic Fields to form a patented combination known as (MP) 2 . This fusion of the two technologies delivers noticeable results without compromising patient comfort.  

The 4D Body applicator on the Venus Legacy™ also features an adjustable pulsed suction mechanism called VariPulse™, which temporarily increases blood circulation, boosts lymphatic drainage, and more. The cellulite reduction treatment on Venus Legacy™ is safe for all skin types.

A study conducted by top international dermatologists demonstrated that the (MP) 2 technology found in Venus Legacy™ is effective in significantly reducing abdominal cellulite. Patients were very satisfied with the results and experienced no adverse effects. The results showed:

  • Reduction in subcutaneous abdominal thickness on the axial and sagittal plane;
  • Average abdominal circumferential reduction of 3.78 cm over the course of the study; and,
  • At 1, 4, and 12 weeks following the final treatment, assessments showed significant improvement in cellulite appearance.

Ultrasound Measurement of a Representative Patient of Abdomen at Axial Plane

(Click the image to view the full size)

Before 1 week after complete treatment
Before chart After chart

Figure 3. Ultrasound Measurement of a Representative Patient of Abdomen at Sagittal Plane

(Click the image to view the full size)

Before 1 week after complete treatment
Before chart After chart

Reduction in subcutaneous abdominal thickness on the axial and sagittal plane, average abdominal circumferential reduction of 3.78 cm over the course of the study, and at one, four, and 12 weeks following the final treatment, assessments showed significant improvement in cellulite appearance.

By combining cutting-edge technology with Venus Concept’s industry-unique business model, the Venus Legacy™ system meets a real need in the marketplace, making it a great addition to any aesthetic practice. To learn more about Venus Legacy™, contact an expert today using the button below.

July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.